市場調查報告書
商品編碼
1261397
2022-2028 年全球子宮切除術設備市場規模、份額、行業趨勢分析報告,按疾病類型、最終用戶、手術方法、地區展望和預測Global Hysterectomy Device Market Size, Share & Industry Trends Analysis Report By Disease Type, By End User, By Surgical Approach, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,子宮切除術設備市場規模預計將達到 4.505 億美元,預測期內復合年增長率為 5.5%。
當女性懷孕時,子宮(也稱為子宮)是嬰兒生長的地方。 通過部分子宮切除術切除子宮,但保留子宮頸。 子宮頸是子宮的頸部。 然後進行全子宮切除術以去除子宮和子宮頸。 此外,還可以通過陰道切口進行子宮切除術,稱為陰道子宮切除術。 他們也可能進□□行機器人手術或腹腔鏡手術,即通過腹部的小切口插入細長器械。
其他子宮切除術,例如如果您的子宮很大,如果您想檢查其他盆腔器官是否有疾病症狀,或者如果您的醫生認為患者的最佳選擇是建議進行開放式手術。您可能需要進行腹式子宮切除術. 子宮切除術可能是治療子宮癌和宮頸癌的最佳方法。 其他治療包括放射療法和化學療法,具體取決於癌症的類型和階段。
COVID-19 影響分析
COVID-19 大流行給世界各地的醫療保健專業人員帶來了挑戰。 結果,資源從其他醫療保健服務中轉移,包括子宮操縱器設備行業,用於護理 COVID-19 患者。 在大流行期間,許多患者在尋求婦科手術治療方面經歷了嚴重的延誤。 許多企業的許多部分都受到了 COVID-19 大流行的影響,包括產品需求、運營、供應鏈、分銷網絡和產品研發能力。 因此,預計 COVID-19將對子宮切除術設備市場產生重大的早期影響。
市場增長因素
肥胖增加
5-19歲兒童青少年超重和肥胖患病率顯著上升,從1975年的約4%上升到2016年的18%以上。底部。 2016 年有超過 1.24 億兒童和青少年肥胖,比 1975 年 5-19 歲兒童中不到 1% 的比例有所增加。 此外,女性 (40%) 比男性 (35%) 更容易肥胖,並且女性的健康在幾個不同方面受到肥胖的顯著影響。 因此,越來越多的女性肥胖症預計會導致子宮肌瘤、子宮癌和慢性盆腔疼痛等問題,從而增加對子宮切除手術的需求並推動子宮切除器械市場的增長。
子宮切除術設備的不斷進步
醫學進步降低了許多手術的風險,現在被認為是微創手術。 這些進步使子宮切除手術比以往任何時候都更安全,對需要手術的女性來說侵入性更小。 機器人手術技術的進步使得通過隱藏在肚臍後面的一英寸切口進行子宮切除術成為可能。 單點機器人子宮切除術具有微創手術的所有優點,並且在大多數情況下不會留下疤痕。
市場製約因素
有無藥物治療或微創手術
當血液供應被切斷時,肌瘤會在數周至數月內死亡並縮小。 這種方法可能適用於不想立即懷孕的女性,因為研究表明,這種手術後流產和其他妊娠問題的風險明顯更高。 子宮肌瘤切除術是一種在不切除子宮的情況下切除肌瘤的外科手術,允許未來懷孕。 與任何保留子宮的手術一樣,肌瘤有復發的可能。 微創手術、激素療法和藥物的可用性可能會改變患者的偏好並限制子宮切除術設備市場的增長。
按疾病類型劃分的前景
根據疾病類型,子宮切除術器械市場分為子宮癌、子宮肌瘤、慢性盆腔痛等。 到 2021 年,慢性盆腔疼痛部分將佔子宮切除術設備市場的最高收入份額。 這是因為它會使女性骨盆衰弱、持續和慢性不適。 慢性盆腔不適常伴有腸易激綜合徵、重度抑鬱症和盆腔炎綜合徵等合併症。 持續性骨盆不適是一種複雜的疾病,有多種潛在原因。
最終用戶視角
按最終用戶劃分,子宮切除術設備市場分為醫院、門診手術中心等。 2021 年,門診手術中心部分在子宮切除術設備市場中佔據了相當大的收入份額。 這種增長歸因於幾個因素,包括對門診護理的高需求、微創手術的使用增加以及在門診手術中心進行的腹腔鏡手術的可負擔性。 由於微創腹腔鏡手術術後並發症的風險較低,預計對移動手術設施的需求將會增加。
手術方法的前景
按手術方法,子宮切除術設備市場分為機器人輔助腹腔鏡子宮切除術、腹腔鏡子宮切除術、經陰道子宮切除術和腹腔鏡子宮切除術。 2021 年,腹部子宮切除術部分在子宮切除術設備市場中的收入份額最高。 這歸因於改善生活質量等好處,尤其是當患者患有持續性骨盆不適或大量不規則出血時。 通過 6-8 英寸的腹部切口切除子宮。 切口從肚臍到恥骨或沿著恥骨髮際線的頂部。
區域展望
按地區分析了北美、歐洲、亞太地區和拉美地區的子宮切除術器械市場。 北美地區將在 2021 年以最大的收入份額引領子宮切除術設備市場。 這是由於該地區的幾個主要參與者和技術改進。 這些領先企業在收購戰略中發揮著不可或缺的作用。 此外,該地區不斷上升的子宮癌患病率、強大的消費者基礎、消費能力和完善的醫療基礎設施預計將推動該地區子宮切除術設備市場的擴張。
The Global Hysterectomy Device Market size is expected to reach $450.5 Million by 2028, rising at a market growth of 5.5% CAGR during the forecast period.
The hysterectomy is the name for the surgical surgery used to remove a woman's uterus. Moreover, this procedure can treat various chronic pain disorders, infections, and some forms of cancer. Depending on the goal of the procedure, a hysterectomy can take various forms. The entire uterus is typically removed in these operations. Hysterectomy can be used to treat uncontrollable vaginal bleeding, persistent pelvic pain, and cancer of the uterus, cervix, or ovaries.
Fibroids, which are benign tumors growing in the uterus, and uterine prolapse, which is when the uterus protrudes from the vagina through the cervix, can also be treated with it joined with adenomyosis, which is a condition in which the lining of the uterus grows into the muscles of the uterus, and pelvic inflammatory disease. A lower belly cut, commonly known as the abdomen, is used during an abdominal hysterectomy to remove the uterus, known as an open procedure.
While a woman is pregnant, the uterus, also known as the womb, is where the baby develops. The uterus is removed with a partial hysterectomy, but the womb's neck remains. The cervix is the womb's neck. Then, the uterus and cervix are removed during a complete hysterectomy. Moreover, a vaginal incision can be used to perform a hysterectomy which is called a vaginal hysterectomy. Alternatively, one might have robotic or laparoscopic surgery, which inserts long, thin equipment through tiny belly incisions.
In place of other hysterectomy procedures, one might require an abdominal hysterectomy if: the uterus is enormous; the doctor wants to examine other pelvic organs for illness symptoms; the doctor suggests an open procedure because it might be the best option for the patient, in their opinion. A hysterectomy may be the best course of treatment for uterine or cervical cancer. Other treatment options may include radiation or chemotherapy, depending on the type of cancer and its stage.
COVID-19 Impact Analysis
The COVID-19 pandemic presented difficulties for healthcare practitioners around the world. As a result, resources were diverted from other healthcare services, including the industry for uterine manipulator devices, to care for COVID-19 patients. Many patients experienced significant delays in receiving gynecologic surgical care during the height of the pandemic. Many parts of numerous businesses, including product demand, operations, supply chains, distribution networks, and the capacity to conduct product research and development, are impacted by the COVID-19 pandemic. As a result, COVID-19 is anticipated to impact the market for hysterectomy device greatly in the initial period.
Market Growth Factors
Rising prevalence of obesity
The prevalence of overweight and obesity among children and adolescents aged 5 to 19 has significantly grown, rising from roughly 4% in 1975 to a little over 18% in 2016. More than 124 million children and teens were obese in 2016, up from less than 1% in 1975 among those aged 5 to 19. Furthermore, women (40%) are more likely to be obese than men (35%), and women's health is majorly impacted by obesity in several distinct ways. Hence, the increasing obesity in women is expected to cause issues like fibroids, uterine cancer, or chronic pelvic pain that will increase the requirement for hysterectomies and boost the hysterectomy device market growth.
The constant advancement of devices used in hysterectomy
Medical advancements have reduced the hazards of many surgeries to the point where they are now regarded as minimally invasive procedures. These developments have made hysterectomy surgery safer and less intrusive than ever for women who require this surgical removal of the uterus. A one-inch incision concealed in the belly button can now be used to perform hysterectomies due to the recent advancements in robotic surgery technology. The single-site robotic hysterectomy offers all the advantages of minimally invasive surgery and, in most cases, results in absolutely no scarring.
Market Restraining Factors
Presence of medications and minimally invasive surgeries
The fibroids die and diminish within a few weeks to months once the blood supply is severed. This method might be better suitable for women who don't want to become pregnant shortly because studies have revealed a considerable risk of miscarriage and other pregnancy issues after this operation. Myomectomy, which allows for future pregnancies, is the surgical removal of the fibroids without removing the uterus. There is a chance of fibroid recurrence, like every other uterus-sparing operation. The availability of minimally invasive procedures, hormone therapies, and medicines might shift patients' preference toward them and restrict the hysterectomy device market growth.
Disease Type Outlook
Based on disease type, the hysterectomy device market is segmented into uterine cancer, fibroids, chronic pelvic pain and others. The chronic pelvic pain segment held the highest revenue share in the hysterectomy device market in 2021. This is because it is a debilitating, persistent, chronic discomfort in a women's pelvis. Chronic pelvic discomfort is frequently accompanied by comorbidities such as irritable bowel syndrome, major depressive illness, or pelvic inflammatory syndrome. Persistent pelvic discomfort is a complicated illness with several potential causes.
End User Outlook
On the basis of end user, the hysterectomy device market is divided into hospitals, ambulatory surgical centers and others. The ambulatory surgical centers segment procured a substantial revenue share in the hysterectomy device market in 2021. The growth is attributed to several factors, including a high desire for outpatient treatments, an increase in the use of minimally invasive procedures, and the affordability of laparoscopic procedures performed in ambulatory surgery centers. The demand for mobile surgery facilities is anticipated to rise due to the lower risk of postoperative complications in minimally invasive laparoscopic surgery.
Surgical Approach Outlook
By surgical approach, the hysterectomy device market is classified into robotic assisted laparoscopic hysterectomy, abdominal hysterectomy, vaginal hysterectomy and laparoscopic hysterectomy. The abdominal hysterectomy segment registered the highest revenue share in the hysterectomy device market in 2021. This is owing to the benefits like improving the quality of life, particularly if the patient suffers from persistent pelvic discomfort or heavy, irregular bleeding. Through a six- to eight-inch abdominal incision, the uterus is removed. The incision is either done from the navel to the pubic bone or along the top of the pubic hairline.
Regional Outlook
Region-wise, the hysterectomy device market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the hysterectomy device market by generating the maximum revenue share in 2021. This is due to several significant players and technical improvements in the region. These leading players play an essential role in acquisition strategies. Furthermore, the region's rising uterine cancer prevalence, strong consumer base, spending power, and established healthcare infrastructure are anticipated to fuel the hysterectomy device market expansion in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, B. Braun Melsungen AG, ConMed Corporation, Johnson & Johnson, Richard Wolf GmbH, Karl Storz SE & Co. KG, The Cooper Companies, Inc., Laborie Medical Technologies (Patricia Industries) (Investor AB), Fortimedix Surgical B.V., and Conkin Surgical Instruments Ltd.
Strategies deployed in Hysterectomy Devices Market
Feb-2023: Laborie announced the acquisition of Novonate and its LifeBubble technology, a device used to raise the foetal head, making birth easier and less traumatic for the mother and baby. Together, the companies are focused on advancing the standard of care for neonates in intensive care.
Nov-2022: Medtronic Private Limited, a division of Medtronic PLC announced the launch of the TruClear system, a mechanical hysteroscopic tissue removal for efficient and safe treatment of intra-uterine anomalies (IUA). Unlike other intrauterine abnormality therapy methods, the TruClear device eliminates intrauterine tissue manually instead of employing a high-frequency electric current. The device is intended to facilitate the treatment of intrauterine illnesses in a less invasive and efficient manner, giving patients the choice to maintain the organ and swiftly return to their regular lives.
Sep-2022: Medtronic together with CARE Hospitals Group, introduced the first gynecology (hysterectomy) procedure in the Asia Pacific leveraging the Hugo robotic-assisted surgery (RAS) system. To provide high-quality patient care at reasonable prices, investments in technology-enabled healthcare solutions are essential. High-quality equipment, like a robotic system, aids in accuracy improvement, shortens hospital stays, and speeds up patient recuperation.
Feb-2022: CooperCompanies signed an agreement to acquire Cook Medical's Reproductive Health Business, a company engaged in manufacturing minimally invasive medical devices for obstetrics, fertility, and gynecology markets. The acquisition added delivery devices to the former company's ObGyn portfolio and would expand its international fertility footprint.
Feb-2022: Laborie acquired Clinical Innovations for continuing to support moms, babies, and medical professionals all over the world by investing in and expanding Clinical Innovations' distinctive product line and specialist channels. The company's ability to serve the specific customer call point of obstetricians, gynecologists, neonatologists, and NICU and L&D nurses will be enhanced by Clinical Innovations' already strong and trusted relationships with physicians and nurses.
Dec-2021: CooperCompanies acquired Generate Life Sciences, a provider of donor sperm and egg for fertility cryopreservation service, fertility treatments, and newborn stem cell storage. With this acquisition, the company would be able to offer fertility clinics and OB/GYNs an even stronger service.
May-2021: CooperSurgical took over obp Medical Corporation, a company that focuses on developing and marketing diversified products comprising single-use vaginal speculums with combined LED illumination. The acquisition complemented CooperSurgical's portfolio of OB/GYN medical devices.
Mar-2021: CooperSurgical completed the acquisition of Safe Obstetric Systems, a company engaged in manufacturing medical devices, Fetal Pillow, an FDA-approved product used to raise the foetal head, making the birth easier and less traumatic for the mother and baby, after a fully dilated caesarean section. The acquisition is a perfect fit for CooperSurgical's mission of women's healthcare advancement.
Market Segments covered in the Report:
By Disease Type
By End User
By Surgical Approach
By Geography
Companies Profiled
Unique Offerings from KBV Research